RUNX2 and prostate cancer: However, at present transcription factors such as RUNX2 are not considered to be drug targets.33 Here, we show that miR-466-mediated attenuation of RUNX2 may be a novel therapeutic approach to regulate tumor growth and bone metastasis in prostate cancer.